First-line trilaciclib combined with immunotherapy plus chemotherapy for extensive-stage small-cell lung cancer:a case report and literature review
REN Guan-ying
SONG Zi-zheng
WANG Xiao-lei
HU Ling
SONG Jin
Abstract：Small-cell lung cancer(SCLC)is one of the most malignant subtypes of lung cancer with rapid tumor progression and a poor prognosis,and also one of the malignancies most difficult to cure in clinical practice.Currently,platinum-based chemotherapy remains the first-line standard treatment for extensive-stage small cell lung cancer(ES-SCLC).Full-dose chemotherapy is warranted for the best efficacy,and the effective rate of first-line treatment is 60%～80%(full-dose),while chemotherapy-induced myelosuppression(CIM)is the main reason hindering adequate chemotherapy.Granulocyte colony-stimulating factor(G-CSF)is commonly used to deal with neutropenia in clinical practice,while this traditional treatment may even cause the depletion of bone marrow hematopoietic reserve function and damage to the normal bone marrow hematopoietic function of patients.Currently,trilaciclib has been approved for the prevention of myelosuppression in ES-SCLC,which can protect hematopoietic stem cells/progenitor cells(HSPCs)fundamentally.In this paper,we report a case of a patient with ES-SCLC treated in our department receiving bone marrow protection with trilaciclib combined with chemotherapy,aiming to provide reference and basis for further research.
Keywords：extensive-stage small cell lung cancermyelosuppressiontrilaciclibCDK4/6 inhibitor
Publication Date：2023-12-15
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：4( 2366-2369 )